Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial) [TREATMENT]

NCT00553345 is registered in ClinicalTrials.gov with University of Birmingham as lead sponsor.

NCT NCT00553345
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00553345 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial) [TREATMENT]
Lead sponsor
University of Birmingham
Phase
Phase 3
Overall status
Unknown status
Start date
December 31, 2005
Completion date
Not reported
Enrollment
515
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer